Palmitoyl Tripeptide-1 vs SHLP2

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Palmitoyl Tripeptide-1

Palmitoyl Tripeptide-1 (Pal-GHK) is a lipopeptide that stimulates collagen production. It's one of two peptides in the Matrixyl 3000 complex, working synergistically with Palmitoyl Tetrapeptide-7.

Full details →

SHLP2

SHLP2 (Small Humanin-Like Peptide 2) is a mitochondrial-derived peptide similar to humanin. It has shown insulin-sensitizing and cytoprotective effects in research, with potential metabolic benefits.

Full details →

Side-by-Side Comparison

Aspect	Palmitoyl Tripeptide-1	SHLP2
Dose Range	500 mcg–2 mg	1 mg–5 mg
Frequency	2x daily	1x daily
Cycle Length	4–12 weeks	4–8 weeks
Route	topical	subcutaneous
Mechanism	Mimics the skin's own mechanism for producing collagen by acting as a messenger peptide that signals fibroblasts to produce more collagen and other extracellular matrix components.	Enhances insulin sensitivity and glucose uptake. Provides cytoprotective effects similar to humanin. May act through similar but distinct receptor pathways.
Typical Dosage	Topical: Typically 2-4% in serums, often combined with Palmitoyl Tetrapeptide-7 as Matrixyl 3000.	Research compound with doses in the microgram to low milligram range studied in animal models. Human dosing not established.
Administration	Topical application 1-2 times daily. The palmitoyl group enhances skin penetration compared to non-lipidated versions.	Subcutaneous or intraperitoneal injection in research settings. Various SHLP analogs (1-6) have different properties.
Side Effects	Very well-tolerated. Suitable for most skin types including sensitive skin.	Limited data. Animal studies suggest good tolerability. May affect glucose metabolism.
Best For	Anti-Aging & Longevity Skin Health & Aesthetics	Fat Loss Anti-Aging & Longevity